Breaking News Instant updates and real-time market news.

WSM

Williams-Sonoma

$49.21

1.91 (4.04%)

, LASR

nLight

$30.00

-1.79 (-5.63%)

18:58
05/23/18
05/23
18:58
05/23/18
18:58

On The Fly: After Hours Movers

UP AFTER EARNINGS: Williams-Sonoma (WSM) up 13.9%... nLight (LASR) up 1.9%... Synopsis (SNPS) up 0.7%. DOWN AFTER EARNINGS: L Brands (LB) down 5.2%... NetApp (NTAP) down 4.0%. ALSO LOWER: Digital Ally (DGLY) down 5.7% after equity offering... Petrobras (PBR) down 2.7% after reports of antitrust regulator scrutiny of natural gas operations... Fiat Chrysler (FCAU) down 2.1%, Toyota Motor (TM) down 1.7% after reports that Trump considers tariffs on auto imports.

WSM

Williams-Sonoma

$49.21

1.91 (4.04%)

LASR

nLight

$30.00

-1.79 (-5.63%)

SNPS

Synopsys

$90.29

1.05 (1.18%)

LB

L Brands

$34.05

0.06 (0.18%)

NTAP

NetApp

$66.61

-0.41 (-0.61%)

DGLY

Digital Ally

$2.55

-0.075 (-2.86%)

FCAU

Fiat Chrysler

$22.47

-0.155 (-0.69%)

TM

Toyota

$134.85

-0.89 (-0.66%)

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 11

    Jun

  • 12

    Jun

  • 10

    Jul

WSM Williams-Sonoma
$49.21

1.91 (4.04%)

03/15/18
BTIG
03/15/18
NO CHANGE
Target $47
BTIG
Sell
Williams-Sonoma price target raised to $47 from $41 at BTIG
BTIG analyst Alan Rifkin raised his price target on Williams-Sonoma to $47 after the company's better than expected Q4 earnings, driven by lower tax rates and upside in comps. Rifkin adds however that the Pottery Barn brand is not "out of the woods", tracking flat on 2-year basis and down 2% on 3-year basis, while the 2-year comps at West Elm decelerated to 18.8% from 23.5% in Q3. The analyst keeps his Sell rating on Williams-Sonoma longer term, citing the company's expectations of EBIT margin guidance implying a 4th straight year of lower profitability.
03/15/18
LOOP
03/15/18
NO CHANGE
Target $55
LOOP
Hold
Williams-Sonoma price target raised to $55 from $47 at Loop Capital
Loop Capital analyst Anthony Chukumba raised his price target on Williams-Sonoma to $55 after Q4 earnings, saying the company's "strategy of accepting lower selling margins drove higher gross profit dollars" while the outlook for FY18 was "rosier than anticipated". The analyst notes that the valuation on the stock of 13.1-times his new FY18 EPS estimate - revised to $4.20 from $3.71 - is appropriate for the company's growth profile, keeping his Hold rating on Williams-Sonoma.
03/14/18
GDHS
03/14/18
UPGRADE
GDHS
Hold
Williams-Sonoma upgraded to Hold from Reduce at Gordon Haskett
01/18/18
WEDB
01/18/18
NO CHANGE
WEDB
Amazon not slowing down in hardlines, says Wedbush
Wedbush analyst Seth Basham continues to see risks from Amazon (AMZN) across the hardlines universe, "but all is not lost." The analyst argues that just as Amazon sees a need for physical retail in some categories, hardlines retailers that deliver a seamless customer experience across the physical and virtual worlds can survive, if not thrive. He believes Home Depot (HD) is the most advanced retailer he covers in responding to the paradigm shift in consumer shopping. Nonetheless, the analyst thinks all retailers need to continue to invest to avoid falling further behind, with Williams-Sonoma (WSM) most at risk from competitive pressures and/or much accelerated investment.
LASR nLight
$30.00

-1.79 (-5.63%)

05/21/18
05/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hostess Brands (TWNK) initiated with a Buy at Berenberg while Flowers Foods (FLO) was initiated with a Hold. 2. Ceridian (CDAY) initiated with an Overweight at Piper Jaffray and MUFG, an Outperform at Wells Fargo, an Equal Weight at Barclays, a Neutral at JPMorgan and Goldman Sachs, a Market Perform at William Blair, as well as a Hold at Deutsche Bank, Canaccord, and Jefferies. 3. nLight (LASR) initiated with an Outperform at Raymond James as well as a Buy at Needham, Canaccord, Stifel, and DA Davidson. 4. VF Corp. (VFC) initiated with a Buy at Argus. 5. Chemours (CC) initiated with a Buy at Vertical Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/21/18
NEED
05/21/18
INITIATION
Target $34
NEED
Buy
nLight initiated with a Buy at Needham
Needham analyst James Ricchiuti initiated nLight (LASR) with a Buy rating and a price target of $34. The analyst notes that much like the larger IPG Photonics (IPGP), nLight is vertically integrated, while also differentiating itself from IPG in terms of its diverse technology. Ricchiuti further states that the company is "leveraged to the strong multi-year secular growth cycle for fiber lasers" and anticipates it to generate 25% growth over the next several years.
05/21/18
ADAM
05/21/18
INITIATION
Target $35
ADAM
Buy
nLight initiated with a Buy at Canaccord
Canaccord analyst Bobby Burleson initiated nLight with a Buy rating, calling it is a pure play on exposure to the high growth fiber laser market. When combined with technological differentiation and significant margin leverage potential through vertical integration, it establishes the company as a compelling long-term investment opportunity, said Burleson, who has a $35 price target on nLight shares.
05/21/18
RAJA
05/21/18
INITIATION
RAJA
Outperform
nLight initiated with an Outperform at Raymond James
SNPS Synopsys
$90.29

1.05 (1.18%)

04/05/18
DADA
04/05/18
UPGRADE
Target $45
DADA
Buy
Cadence Design upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Thomas Diffely upgraded Cadence Design (CDNS) to Buy from Neutral and kept his $45 price target. Diffely points to the divergence of strong business activity against weak stock performance for the company, saying the 20% slide since the end of January creates an "attractive buying opportunity". The analyst notes that Cadence Design is gaining market share, mainly from Mentor Graphics (MENT) and no longer trades at a "meaningful" premium to Synopsys (SNPS), adding that he is positive on the company's short and long-term electronic design automation opportunity.
01/18/18
KEYB
01/18/18
NO CHANGE
KEYB
Cost savings emerge as 'killer app' for artificial intelligence, says KeyBanc
Over the past 35 days, KeyBanc analyst Brent Bracelin hosted meetings at Adobe (ADBE), Autodesk (ADSK), Algorithmia, Cloudera (CLDR), Coupa (COUP), Facebook (FB), Guidewire (GWRE), Netflix (NFLX), NVIDIA (NVDA), Salesforce (CRM), SAP, Synopsys (SNPS), Twilio (TWLO), Tableau (DATA), Talend (TLND), Veeva (VEEV), Workday (WDAY), and Zendesk (ZEN) as part of an AI & Cloud-themed field trip. The analyst notes that cost savings have emerged as the "killer app" for artificial intelligence, and large enterprise interest in migrating back-office apps to cloud has been slow, but is picking up, conversational AI and bot activity is yielding real cost savings. Further, Bracelin sees 2018 as a defining year for enterprise AI applications, and is most impressed by enterprise AI initiatives at Microsoft (MSFT), Zendesk, Guidewire, and Adobe.
12/12/17
JPMS
12/12/17
DOWNGRADE
Target $87
JPMS
Underweight
Synopsys downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Sterling Auty downgraded Synopsys to Underweight with an unchanged price target of $87 in conjunction with his 2018 annual outlook for Software Technology. The analyst does not expect the "exceptional performance" in Software during 2017 to repeat in 2018. As such, he's moderating his bullish outlook into next year.
12/01/17
NEED
12/01/17
NO CHANGE
Target $100
NEED
Buy
Synopsys price target raised to $100 from $83 at Needham
Needham analyst Richard Valera raised his price target on Synopsys to $100 after a Q4 earnings beat, saying the company enters FY18 with good momentum amid a stronger macro backdrop, ongoing strength in IP and hardware, and growing scale of its Software Integrity business. Valera keeps his Buy rating despite the company trading well above its historical multiples, noting that Synopsys is the only Buy-rated firm in his coverage of mid-cap technical software names.
LB L Brands
$34.05

0.06 (0.18%)

05/11/18
05/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kohl's (KSS) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Binetti saying he sees first quarter same store sales risk due to cold weather damaging industry traffic and Kohl's being more weather sensitive than its peers, and slightly lowered his Q1 EPS estimate on the stock. 2. Symantec (SYMC) downgraded to Sell from Neutral at MoffettNathanson, to Equal Weight from Overweight at Barclays and First Analysis, to Perform from Outperform at Oppenheimer, and to Neutral from Buy at BTIG, to Neutral from Outperform at Macquarie, and to Neutral from Overweight at Piper Jaffray. 3. AMC Networks (AMCX) downgraded to In Line on valuation at Evercore ISI with analyst David Joyce citing valuation. 4. L Brands (LB) downgraded to Neutral from Overweight at Atlantic Equities. 5. Presidio (PSDO) downgraded to Sector Perform from Outperform at RBC Capital and to Market Perform from Outperform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/18
SBSH
05/14/18
UPGRADE
SBSH
Buy
L Brands upgraded to Buy from Neutral at Citi
05/14/18
05/14/18
UPGRADE
Target $38

Buy
Citi upgrades L Brands to Buy with valuation 'just too cheap to ignore'
As previously reported, Citi analyst Paul Lejuez upgraded L Brands to Buy from Neutral, though he acknowledges this is "not an 'all's clear' type of call" and that things may get worse before they get better. However, he feels consensus sentiment has become so bearish and the stock's valuation is "just too cheap to ignore," he tells investors. He notes the dividend yield is now 7.4% and he believes the dividend is safe. Lejuez lowered his price target on L Brands shares, however, to $38 from $64.
05/14/18
05/14/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Buy from Neutral at BofA/Merrill with analyst Ken Hoexter saying he thinks UPS's Network Transformation plan that will be launched in a couple months will improve its cost structure and margins, and could prove to be the turning point for the company and drive the multiple back toward historical levels. 2. FMC Corporation (FMC) upgraded to Buy from Neutral at Goldman Sachs with analyst Robert Koort saying the solid first quarter report convinced him to change his rating as pro forma orgnaic growth rates were very strong, and earnings contribution from the DowDuPont (DWDP) acquisition far exceeded his expectations. 3. L Brands (LB) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying he acknowledges this is "not an 'all's clear' type of call," and that things may get worse before they get better, however, he feels consensus sentiment has become so bearish and the stock's valuation is "just too cheap to ignore." 4. Lear (LEA) upgraded to Outperform from In Line at Evercore ISI with analyst Chris McNally saying he sees double digit earnings growth through 2020 with earnings growth set to accelerate in 2019 on the back of the GM truck launch and acceleration of E-Systems given megatrends in Electrification & Connectivity. 5. CSX (CSX) upgraded to Neutral from Sell at Goldman Sachs with analyst Matt Reustle citing better risk/reward following successful execution of Q1 network initiatives. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NTAP NetApp
$66.61

-0.41 (-0.61%)

04/17/18
WBLR
04/17/18
UPGRADE
WBLR
Outperform
NetApp upgraded to Outperform from Market Perform at William Blair
William Blair analyst Jason Ader upgraded NetApp to Outperform.
04/17/18
WBLR
04/17/18
UPGRADE
WBLR
Outperform
William Blair sees NetApp business surge continuing, upgrades to Outperform
William Blair analyst Jason Ader upgraded NetApp to Outperform from Market Perform and "significantly" raised his estimates for the company. In a research note partially titled "The Surge Looks Sustainable," the analyst says recent channel checks erased his skepticism of the recent surge in NetApp's business. The stock's risk/reward still skews "substantially positive" at the cash-adjusted price-to-earnings multiple of 12.6 times his new 2019 estimate, Ader tells investors. He believes NetApp's "business can continue to surge for the next few years."
05/10/18
OTRG
05/10/18
NO CHANGE
OTRG
NetApp channel checks positive, says OTR Global
OTR Global said its checks with NetApp's channel partners indicate that its flash products and cloud strategy drove improving win rates and kept sales strong during the company's Q4.
05/18/18
LOOP
05/18/18
NO CHANGE
Target $85
LOOP
Buy
NetApp price target raised to $85 from $75 at Loop Capital
Loop Capital analyst Ananda Baruah raised his price target on NetApp to $85 ahead of next week's earnings, citing the "ongoing momentum" in IT spending and acceleration in the latest quarter. The analyst adds that the company's most recent guidance does not include its planned $4B stock buyback, which could add about $1 in EPS to their guidance, and also calls the April quarter revenue outlook "conservative". Baruah keeps his Buy rating on NetApp while also maintaining his view that the stock price could reach as high as $105 per share.
DGLY Digital Ally
$2.55

-0.075 (-2.86%)

11/16/17
MAXM
11/16/17
NO CHANGE
Target $4
MAXM
Buy
Digital Ally price target lowered to $4 from $9 at Maxim
Maxim analyst Brian Kinstlinger lowered his price target on Digital Ally (DGLY) to $4, saying Q3 results showed revenue remains depressed while the low $316k cash balance means the company will have to raise cash before year-end. Kinstlinger keeps his Buy rating, noting the company's strategic alternatives review as well as its patent infringement suit against Axon (AAXN) that could produce shareholder value, but says it is difficult to predict the outcome of litigation.
04/13/18
MAXM
04/13/18
DOWNGRADE
MAXM
Hold
Digital Ally downgraded to Hold from Buy at Maxim
04/13/18
04/13/18
DOWNGRADE

Hold
Digital Ally downgraded to Hold on expectations for more share losses at Maxim
As previously reported, Maxim analyst Brian Kinstlinger downgraded Digital Ally (DGLY) to Hold from Buy after the company reported revenue that missed his estimates, which the company blamed on competitor Axon (AAXN) giving away free product and cloud storage for one year. Kinstlinger sees Digital Ally's core business losing additional market share and believes additional dilution of shareholders capital raising is likely in the next six months.
FCAU Fiat Chrysler
$22.47

-0.155 (-0.69%)

04/25/18
JEFF
04/25/18
DOWNGRADE
Target $26
JEFF
Hold
Fiat Chrysler downgraded to Hold from Buy at Jefferies
Jefferies analyst Philippe Houchois downgraded Fiat Chrysler to Hold while raising his price target for the shares to $26 from $24. The analyst believes "meaningful upside" from current share levels would require "supernormal profits" or "black swan events" such as a takeover. He cites valuation for the downgrade to Hold.
04/09/18
04/09/18
UPGRADE
Target $48

Overweight
GM upgraded to Overweight on infrastructure bill potential at Morgan Stanley
As previously reported, Morgan Stanley analyst Adam Jonas upgraded General Motors (GM) to Overweight from Equal Weight, as he sees room for positive earnings revisions for GM, Ford (F) and Fiat Chrysler (FCAU) as investors better understand the impact on U.S. pick-up truck sales from a potential passage of a U.S. infrastructure bill. The firm's economics team estimates a bull case of as much as $2.4T in U.S. infrastructure spending over a 10-year period, which primarily would affect automakers through the sale of highly-profitable pickup trucks, said Jonas, who noted that greater infrastructure spending typically does coincide with increased pickup sales. Jonas raised his price target on GM shares to $48 from $45 and increased his price target on Fiat Chrysler to EUR23 from EUR22 per share.
03/21/18
NOMU
03/21/18
INITIATION
NOMU
Neutral
Fiat Chrysler initiated with a Neutral at Nomura Instinet
Nomura Instinet started Fiat Chrysler with a Neutral rating and EUR 19 price target.
05/22/18
HSBC
05/22/18
INITIATION
HSBC
Buy
Fiat Chrysler initiated with a Buy at HSBC
HSBC started Fiat Chrysler with a Buy rating.
TM Toyota
$134.85

-0.89 (-0.66%)

03/13/18
MSCO
03/13/18
NO CHANGE
MSCO
Morgan Stanley compares automakers to Facebook, Apple in 'Auto 2.0' model
Morgan Stanley analyst Adam Jonas noted that auto companies' valuations have compressed to extremely low levels, but he believes that a move from a vehicle ownership model to a transportation subscriber model could expand the revenue opportunities for the potential "tollkeepers" for the monetization of content and data by "nearly an order of magnitude." Looking at U.S. technology leaders Facebook (FB) and Apple (AAPL), which are both valued on their installed base/subscriber models, can "offer valuable clues" regarding the opportunity for General Motors (GM) and other auto OEMs, said Jonas. Viewing the OEMs though the lens of a subscription model, which should be less cyclical and potentially less capital intensive over time than the current auto model, is relevant to analyzing auto stocks, according to Jonas, who adds that it is still too early to call a winner or loser in "Auto 2.0." Other publicly traded legacy automakers include Fiat Chrysler (FCAU), Ford (F), Honda (HMC), Nissan (NSANY), Toyota (TM), Volkswagen (VLKAY) and Daimler (DDAIF).
03/27/18
UBSW
03/27/18
UPGRADE
UBSW
Neutral
Toyota upgraded to Neutral from Sell at UBS
03/27/18
03/27/18
UPGRADE

Neutral
Toyota upgraded to Neutral with manufacturing margins seen near bottom at UBS
As previously reported, UBS upgraded Toyota to Neutral from Sell as the firm believes the company's manufacturing margin should bottom in FY18. Following a recent Asia tour, the firm also forecasts emerging markets like ASEAN to turn to positive year-over-year growth, UBS noted in its upgrade. UBS raised its price target on Toyota to Y7,000 from Y6,400.
03/01/18
BOFA
03/01/18
UPGRADE
BOFA
Neutral
Toyota upgraded to Neutral from Underperform at BofA/Merrill

TODAY'S FREE FLY STORIES

OHI

Omega Healthcare

$31.86

0.07 (0.22%)

21:21
06/24/18
06/24
21:21
06/24/18
21:21
Downgrade
Omega Healthcare rating change at Wells Fargo »

Omega Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

20:05
06/24/18
06/24
20:05
06/24/18
20:05
Hot Stocks
MiniMed 670G system real-world data show improved time in range »

Medtronic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

GE

General Electric

$13.05

0.29 (2.27%)

, AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

19:31
06/24/18
06/24
19:31
06/24/18
19:31
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

GE

General Electric

$13.05

0.29 (2.27%)

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

BRK.B

Berkshire Hathaway

$188.89

0.05 (0.03%)

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

CMCSA

Comcast

$33.82

1.02 (3.11%)

CMCSK

Comcast

$0.00

(0.00%)

C

Citi

$67.20

-0.43 (-0.64%)

TWTR

Twitter

$45.90

0.68 (1.50%)

MD

Mednax

$44.99

-0.11 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 26

    Jul

  • 27

    Jul

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

OGE

OGE Energy

$34.95

0.15 (0.43%)

19:25
06/24/18
06/24
19:25
06/24/18
19:25
Downgrade
OGE Energy rating change at Goldman Sachs »

OGE Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Acquired by T

$0.00

(0.00%)

, CMCSA

Comcast

$33.82

1.02 (3.11%)

19:18
06/24/18
06/24
19:18
06/24/18
19:18
Hot Stocks
Box Office Battle: 'Jurassic World: Fallen Kingdom' wins weekend with $150M »

Universal (CMCSA; CMCSK)…

TWX

Acquired by T

$0.00

(0.00%)

CMCSA

Comcast

$33.82

1.02 (3.11%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$50.36

1.15 (2.34%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

LGF.A

Lionsgate

$26.90

0.6 (2.28%)

DIS

Disney

$106.37

0.48 (0.45%)

VIAB

Viacom

$30.27

-0.13 (-0.43%)

VIA

Viacom

$35.70

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

, BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

18:53
06/24/18
06/24
18:53
06/24/18
18:53
Periodicals
Amazon/Berkshire/JPMorgan venture takes aim at middlemen, Bloomberg says »

The health venture…

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

BRK.B

Berkshire Hathaway

$188.89

0.05 (0.03%)

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 12

    Oct

GE

General Electric

$13.05

0.29 (2.27%)

18:42
06/24/18
06/24
18:42
06/24/18
18:42
Periodicals
General Electric nearing deal to sell industrial engines unit, WSJ says »

General Electric is close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

18:25
06/24/18
06/24
18:25
06/24/18
18:25
Conference/Events
Novo Nordisk to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

ERYP

Erytech Pharma

$0.00

(0.00%)

18:17
06/24/18
06/24
18:17
06/24/18
18:17
Hot Stocks
Erytech Pharma confirms strategic focus of eryaspase on solid tumors »

Erytech Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$13.58

0.51 (3.90%)

18:12
06/24/18
06/24
18:12
06/24/18
18:12
Hot Stocks
Lexicon announces positive 52-week results from Sotagliflozin inTandem1 study »

Lexicon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 22

    Mar

PODD

Insulet

$97.37

0.5697 (0.59%)

18:09
06/24/18
06/24
18:09
06/24/18
18:09
Hot Stocks
Insulet presents positive results for Omnipod Horizon Hybrid Closed-Loop System »

Insulet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

18:00
06/24/18
06/24
18:00
06/24/18
18:00
Hot Stocks
Real-World data show advantages in people treated with Eli Lilly's Trulicity »

People with type 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LXRX

Lexicon

$13.58

0.51 (3.90%)

17:56
06/24/18
06/24
17:56
06/24/18
17:56
Hot Stocks
Lexicon announces positive 52-week results from Sotagliflozin inTandem2 study »

Lexicon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 22

    Mar

DGX

Quest Diagnostics

$112.13

0.93 (0.84%)

17:53
06/24/18
06/24
17:53
06/24/18
17:53
Hot Stocks
Employer wellness programs may reduce risk of developing chronic conditions »

Employer wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

17:44
06/24/18
06/24
17:44
06/24/18
17:44
Hot Stocks
New data reinforce potential of Eli Lilly's Ultra Rapid Lispro in diabetes »

Eli Lilly's ultra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

17:38
06/24/18
06/24
17:38
06/24/18
17:38
Hot Stocks
Eli Lilly announces findings from new analyses of EMPA-REG OUTCOME trial »

Boehringer Ingelheim and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

CTRV

ContraVir Pharmaceuticals

$1.47

-0.06 (-3.92%)

17:30
06/24/18
06/24
17:30
06/24/18
17:30
Conference/Events
ContraVir Pharmaceuticals to hold a business news update conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZFGN

Zafgen

$6.94

0.32 (4.83%)

17:27
06/24/18
06/24
17:27
06/24/18
17:27
Hot Stocks
Zafgen announces positive full results in phase 2 clinical trial of ZGN-1061 »

Zafgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNKD

MannKind

$1.98

0.02 (1.02%)

17:22
06/24/18
06/24
17:22
06/24/18
17:22
Hot Stocks
MannKind presents positive Afrezza clinical data from STAT, AFFINITY studies »

MannKind announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$61.46

0.295 (0.48%)

16:53
06/24/18
06/24
16:53
06/24/18
16:53
Hot Stocks
Merck presents new data from comparative trials in Type 2 diabetes »

Merck, known as MSD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 10

    Sep

  • 23

    Oct

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

04:55
06/24/18
06/24
04:55
06/24/18
04:55
Conference/Events
Novo Nordisk to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

A

Agilent

$62.79

-0.24 (-0.38%)

, ABT

Abbott

$61.93

0.19 (0.31%)

04:55
06/24/18
06/24
04:55
06/24/18
04:55
Conference/Events
American Diabetes Association to hold a conference »

78th Scientific Sessions…

A

Agilent

$62.79

-0.24 (-0.38%)

ABT

Abbott

$61.93

0.19 (0.31%)

AKCA

Akcea Therapeutics

$26.24

0.4 (1.55%)

AMGN

Amgen

$184.86

-1.14 (-0.61%)

AZN

AstraZeneca

$35.06

-0.095 (-0.27%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$64.63

1.15 (1.81%)

DXCM

DexCom

$99.52

-0.2 (-0.20%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

IRWD

Ironwood

$19.35

0.74 (3.98%)

JNJ

Johnson & Johnson

$122.81

1.36 (1.12%)

MDT

Medtronic

$86.80

0.51 (0.59%)

MNKD

MannKind

$1.98

0.02 (1.02%)

WAKE

Wake Forest Bancshares Inc.

$0.00

(0.00%)

VLRX

Valeritas

$1.39

0.035 (2.58%)

TNDM

TNDM

SNY

Sanofi

$39.98

0.96 (2.46%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$4.76

-0.2 (-4.03%)

REGN

Regeneron

$331.82

2.81 (0.85%)

PODD

Insulet

$97.37

0.5697 (0.59%)

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

MRK

Merck

$61.46

0.295 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 28

    Jun

  • 02

    Jul

  • 06

    Jul

  • 12

    Jul

  • 17

    Jul

  • 18

    Jul

  • 11

    Aug

  • 27

    Aug

  • 30

    Aug

  • 10

    Sep

  • 06

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 22

    Mar

AMGN

Amgen

$184.86

-1.14 (-0.61%)

12:23
06/23/18
06/23
12:23
06/23/18
12:23
Hot Stocks
Amgen's Repatha 'significantly reduced' LDL-C, non-HDL-C in Type 2 diabetes »

Amgen announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

12:18
06/23/18
06/23
12:18
06/23/18
12:18
Hot Stocks
Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes »

Two investigational doses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

IRWD

Ironwood

$19.35

0.74 (3.98%)

12:14
06/23/18
06/23
12:14
06/23/18
12:14
Hot Stocks
Ironwood announced Praliciguat phase IIa study data »

Ironwood Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.